Macrogenics (FRA:M55) Growth Rank: 2 (As of Sep. 09, 2026) — 33% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:M55 Macrogenics Inc FRA:M55
50 GF Score
Price €3.74
GF Value €3.20
! 6 Warning Signs
View Full Analysis

What is Macrogenics Growth Rank?

Macrogenics FRA:M55 50 Growth Rank is 2 as of Sep. 09, 2026, which is 33% below its 10-year median of 3.00. GuruFocus rates FRA:M55 with a GF Score™ of 50/100 and a GF Value™ of €3.20. The stock has 6 warning signs investors should review.

Macrogenics has the Growth Rank of 2.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

FRA:M55 vs WHWK, SRZN, SION: Growth Rank Comparison

For the Biotechnology subindustry, Macrogenics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Macrogenics Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Macrogenics's Growth Rank distribution charts can be found below:

* The bar in red indicates where Macrogenics's Growth Rank falls into.


FRA:M55
50GF Score
Macrogenics Inc FRA:M55
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 2 mean?
Macrogenics (FRA:M55) has a Growth Rank of 2 as of Sep. 09, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Macrogenics and its competitors. This is 33% below median its historical median of 3.00. Over the past decade, Macrogenics' Growth Rank has ranged from 1.00 to 8.00.
Is Macrogenics' Growth Rank too high?
Macrogenics' current Growth Rank of 2 is 33% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. Overall, Macrogenics has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Macrogenics' Growth Rank compare to WHWK and SRZN?
Macrogenics' Growth Rank of 2 can be compared against companies in the Biotechnology industry. Historically, Macrogenics' own Growth Rank has ranged from 1.00 to 8.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Macrogenics and its competitors. Macrogenics's current Growth Rank is 2, which is 33% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macrogenics stock overvalued right now?
Macrogenics (FRA:M55) has a current Growth Rank of 2. The stock's GF Value™ is €3.20, compared to a current price of €3.74 — trading 16.9% above its estimated fair value. The current Growth Rank is 2, which is 33% below median its 10-year median of 3.00. Macrogenics' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Macrogenics (FRA:M55), the current Growth Rank is 2 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Macrogenics (FRA:M55) Overvalued in 2026?

Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued. The current stock price of €3.74 is trading 16.9% above its estimated GF Value™ of €3.20.

Key valuation signals for FRA:M55:

  • Growth Rank: 2 (33% below median its 10-year median of 3.00)
  • GF Value™: €3.20 vs. price of €3.74 (16.9% above fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the FRA:M55 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Macrogenics Business Description

Other Exchanges MGNX:USA
Address 9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
50GF Score

Get the complete analysis for FRA:M55

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.74
Price
€3.20
GF Value